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Programmed cell death protein1 (PD1)-expression
in the microenvironment of classical Hodgkin 
lymphoma at relapse after conventional 
chemotherapy and at relapse on anti-PD1 treatment
We are grateful to Taylor et al. for their comments on
our results to programmed cell death protein 1 (PD1)
expression in sequential biopsies of classical Hodgkin
lymphoma (cHL) patients with progressive disease under
anti-PD1 treatment. Furthermore, we appreciate sharing
their results to PD1- and PD ligand 1 (PDL1) expression
in biopsies of a case series of cHL patients with relapse
post conventional chemotherapy.
In their case series, Taylor et al. found no evidence of a
shift in PD1 or PDL1 expression at relapse after
chemotherapy in paired lymph node biopsies. These
results are in line with the analyses of Schnitter et al. who
examined PD1 expression in 16 and PDL1 expression in
13 paired biopsies at initial diagnosis and after first-line
chemotherapy (Schnitter et al., manuscript in prepara-
tion). Both analyses thus support our hypothesis that the
increase of PD1+ T cells in Hodgkin/Reed-Sternberg cell
(HRSC) vicinity is associated with anti-PD1 treatment
and is not a general feature of relapsing disease. In 4 of 9
analyzed patients (patient 2, 7, 8 and 9) with progressive
disease of cHL, under anti-PD1 treatment, we could doc-
ument a notable increase of PD1+ T cells in HRSC vicini-
ty.1
Additional analyses are required to further characterize
the described PD1+ T cells in HRSC vicinity. As already
discussed by Taylor et al., PD1 expression is a widespread
marker of T-cell activation, but might also indicate the
presence of follicular helper T cells as well as the devel-
opment of exhausted, hyperactivated T cells as possible
mechanism of resistance to anti-PD1 treatment.2
Appropriate T-cell activation as the reason for document-
ed increase of PD1+ T cells seems rather unlikely since all
most recent biopsies were taken in relapse on anti-PD1
treatment. The latter hypothesis is supported by the
observation that in 2 patients with progressive disease
under anti-PD1 treatment and documented increase of
PD1+ positive T cells (patients 7 and 8), a disease stabi-
lization could be achieved by doubling the dose of the
anti-PD1 antibody.1 However, as already mentioned by
Taylor et al., the interpretation of our results in patient 8
is even more complicated since the histology of the most
current relapse changed to a lymphocyte-rich (LR) sub-
type of cHL, and LR cHL in fact differs from other sub-
types of cHL in respect to PD1-positive cells within the
tumor specimen. 
A direct contact (rosette) of HRSC to PD1 strongly pos-
itive T cells has been described as a characteristic feature
of nodular lymphocyte predominant HL (nLPHL) and of
LR cHL. The diagnosis of nLPHL could be excluded in the
most current tumor biopsy of patient 8 as well as in the
subsequent case series. Taylor et al. reported a significant-
ly higher PD1 expression in their LR cHL cases compared
to nodular sclerosis or mixed cellularity cHL cases.3 In
order to further evaluate rosetting of HRSC by PD1 pos-
itive T cells as well as PD1 and PDL1 expression in LR
cHL, we have analyzed 10 specimens of LR cHL obtained
at diagnosis before any treatment by immunohistochem-
istry as previously described1 and by fluorescence multi-
staining. Furthermore, we analyzed the PDL1 gene copy
number by fluorescence in situ hybridization (Zytovision,
Bremerhaven, Germany). As shown in table 1 and illus-
trated in figure 1, the majority of these LR cHL cases
show rosetting PD1-positive T cells. HRSC lack PD-L1
expression and copy number alterations. These findings
confirm the observation by Taylor et al. In contrast to the
results of Roemer et al. in 2016, even in cases with
detectable PDL1 polysomy or copy gain, no relevant
PDL1 expression could be detected.4 More analyses are
required to understand whether inverse correlation of
PD-L1 on HRSC and PD1 on rosetting T cells is a feature
restricted to the LR variant of cHL.  
However, the documented lack of PDL1 expression on
HRSC in this case series of LR cHL and in the analyses of
Sakakibara et al. in 20185 stands in marked contrast to our
observation that in patient 8 of our case series, 90% of
HRSC of the most current tumor biopsy showed a strong
PDL1 expression. This case of LR cHL might therefore be
regarded as an atypical variant of this subtype which may
have developed from mixed cellularity or nodular sclero-
sis subtype under the influence of immunomodulatory
treatment. 
We are aware of the limitations of our analysis, includ-
ing the mentioned predominantly descriptive nature of
our results, a limited analysis of markers due to scarcity
of tissue in relapse, cross-tissue comparison and a het-
erogenous patient cohort. Taylor et al. listed the compar-
ison of PD1/PDL1 expression across different cHL histo-
logical subtypes as an additional limitation of our analy-
sis; we agree that assessment of possible dynamics in
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Table 1. Analysis of PD1 and PDL1 expression in a case series of LR cHL.
Case number Diagnosis Age Sex PDL1 IHC PDL1 FISH amplification PD1 rosetts IHC
1 lymphocyte-rich cHL 21 m − normal present
2 lymphocyte-rich cHL 58 F +/- n.e. present
3 lymphocyte-rich cHL 47 m +/- polysomy present
4 lymphocyte-rich cHL 65 m − n.e. present
5 lymphocyte-rich cHL 20 f + normal Absent
6 lymphocyte-rich cHL 50 m − normal present
7 lymphocyte-rich cHL 51 m +/- normal present
8 lymphocyte-rich cHL 81 m − copy gain present
9 lymphocyte-rich cHL 56 m − n.e. Absent
10 lymphocyte-rich cHL 42 m − polysomy Present
cHL: classical Hodgkin Lymphoma; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization; n.e.: not evaluable; +: majoriity of HRSC positive; +/-: partial expres-
sion in HRS; -: no expression in HRSC.
PD1/PDL1 expression in sequential biopsies might be
considerably complicated by different histological sub-
types. However, as indicated in retrospective analyses,
change in cHL subtype in relapsed disease is frequent,
and even more frequently, histopathological differentia-
tion of the subtype is not possible.6 Thus, from our point
of view, the analyzed tumor samples are representative
for the examined patient cohort.
Despite the limitations listed, our results might con-
tribute to the understanding of acquired resistance to
anti-PD1 treatment in cHL and, as also concluded by
Taylor et al., are therefore worth validating in a larger
patient cohort. Furthermore, our data, the data presented
by Taylor et al. as well as previously published data by
Sakakibara et al. suggest that the LR subtype of cHL dif-
fers in PD1 and PDL1 biology from other subtypes of
cHL.
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Figure 1. Immunohistochemical analysis and fluorescence in situ hybridization in a case of lymphocyte-rich classical Hodgkin lymphoma (case 8 from Table
1). A. Immunohistochemical staining for PD1 in case 8 (table 1) showing rosettes of PD1-positive T cells in vicinity of HRSC (arrows). B. Staining for PDL1 remains
negative by conventional immunohistochemistry. C. Minor copy gain by fluorescence in situ hybridization with green arrows indicating the PDL1 probe and red
arrows the centromeric control probe. D. Immunofluorescence multi-staining for Pax5 (red) to indicate HRSC and B cells and PDL1 (green). Blue colour repre-
sents DAPI nuclear staining. All images original magnification 1000x. 
